Institute on Psychiatric Services
Industry-Supported Breakfast, Lunch, and Dinner Symposia

Friday, October 2

Noon-1:30 p.m.
Diagnosis and Treatment Advances in Manic Depression
Chair: Hagop S. Akiskal, M.D.
Supported by Abbott Laboratories

7:30 p.m.-10:30 p.m.
Atypical Antipsychotics in Selected Patients
Chair: Prakash S. Masand, M.D.
Supported by Janssen Pharmaceutica and Research Foundation

Saturday, October 3

6:30 a.m.-8 a.m.
A New Look at Typical Neuroleptics
Chair: Stephen M. Stahl, M.D., Ph.D.
Supported by Watson Laboratories Inc.

Noon-1:30 p.m.
New Research Findings and Treatment Strategies for Recurrent and Chronic Depression
Chair: A. John Rush, M.D.
Supported by Bristol-Myers Squibb

Emerging Concepts for Treatment of Dementia
Chair: Dilip V. Jeste, M.D.
Supported by Janssen Pharmaceutica and Research Foundation

7 p.m.-10 p.m.
Therapeutic Strategies for Alzheimer's Disease
Chair: George T. Grossberg, M.D.
Supported by Novartis Pharmaceuticals Corporation

Depression and Its Impact on the Body and Mind
Chair: Martin B. Keller, M.D.
Supported by U.S. Pharmaceuticals, Pfizer Inc.

Sunday, October 4 6:30 a.m.-8 a.m.
Use of Antipsychotics in Bipolar Disorder
Chair: Paul E. Keck Jr., M.D.
Supported by Eli Lilly and Company

Noon-1:30 p.m.
Sexual Dysfunction, Depression, and Antidepressants
Chair: Troy L. Thompson II, M.D.
Supported by Organon Inc.

Schizophrenia: Charting a Course Through Illness
Chair: S. Charles Schulz, M.D.
Supported by U.S. Pharmaceuticals, Pfizer Inc.

7 p.m.-10 p.m.
Depression and Its Subtypes: A Treatment Update
Chair: Jerrold F. Rosenbaum, M.D.
Supported by Glaxo Wellcome Inc.

Violence and Mental Illness: An Overview
Chair: W. Walter Menninger, M.D.
Supported by Eli Lilly and Company

Monday, October 5

6:30 a.m.-8 a.m.
Practical Aspects to Improving Outcomes in Schizophrenia
Chair: Peter Weiden, M.D.
Supported by Zeneca Pharmaceuticals

Noon-1:30 p.m.
Intervention for Refractory Bipolar Disorder
Chair: Gary S. Sachs, M.D.
Supported by Glaxo Wellcome Inc.

Perennial Issues in the Management of Depression
Chair: Alan F. Schatzberg, M.D.
Supported by Wyeth-Ayerst Laboratories

5:30 p.m.-8:30 p.m.
Accelerating Antidepressant Response in the Severely III
Chair: Steven P. Roose, M.D.
Supported by Forest Laboratories Inc.

Click here for registration information